Share on LinkedInShare on LinkedIn

ARTICLE · 31 DECEMBER 2025

UPC Aligns With The EPO In Allowing Functional Antibody Claims

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

While the U.S. Supreme Court rejected Amgen's functionally defined anti-PCSK9 antibody claims based on its high bar for enablement, the European Patent Office ("EPO") found such broad antibody claims allowable.

United StatesIntellectual Property

In Short

The Background: While the U.S. Supreme Court rejected Amgen's functionally defined anti-PCSK9 antibody claims based on its high bar for enablement, the European Patent Office ("EPO") found such broad antibody claims allowable. Amgen's battle was also fought at the Unified Patent Court ("UPC"), with the first instance denying an inventive step.

The Result: The UPC Court of Appeal ("CoA") recently overturned the first-instance decision. With its ruling on November 25, 2025 (UPC_CoA_529/2024), the UPC aligns its standard on sufficiency for functionally defined antibody claims with that established by the EPO jurisprudence, while rejecting a strict adherence to the EPO's "problem-solution" approach for assessing an inventive step.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from